CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Exondys (eteplirsen) and Vyondys (golodirsen) for Duchenne Muscular Dystrophy

This policy defines Blue Cross Blue Shield Rhode Island's coverage stance for the antisense oligonucleotides eteplirsen and golodirsen for treatment of Duchenne muscular dystrophy and summarizes the supporting clinical/regulatory evidence relevant to coverage.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyExondys (eteplirsen) and Vyondys (golodirsen) for Duchenne Muscular Dystrophy

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateOct 1, 2020

Next Review DateN/A

Key ActionVerify member-specific benefits with the provider call center and refer to the Evidence of Coverage before pursuing treatment.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Not coveredCoverage stance

J1428, J1429Not covered codes

InsufficientClinical conclusion

2016, 2019FDA approvals

Coverage Determination and Rationale

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Overall coverage determination

Covered when ALL of the following are met:

Coverage stance: Eteplirsen and golodirsen are not covered for all indications including treatment of Duchenne muscular dystrophy due to insufficient evidence of clinical benefit.

Policy cites lack of confirmatory clinical benefit despite observed increases in dystrophin; FDA accelerated approvals require confirmatory trials.

The use of eteplirsen and golodirsen is not covered for all indications, including treatment of Duchenne muscular dystrophy, because the evidence is insufficient to determine effects on health outcomes. The policy explicitly lists the following HCPCS codes as not covered: J1428 (Injection, eteplirsen, 10 mg) and J1429 (Injection, golodirsen, 10 mg).

Services that are determined to be not medically necessary or that are non‑covered benefits under a member’s subscriber or employer agreement are excluded from coverage. Providers must follow the member’s Evidence of Coverage and participation agreement; if a service is non‑covered, the provider may not charge the member unless the member was informed and provided prior written agreement to assume financial responsibility.

The available clinical evidence does not demonstrate that treatment with eteplirsen or golodirsen produces meaningful clinical benefit. Trials and follow‑up studies showed small increases in dystrophin protein on muscle biopsy (for eteplirsen: Western blot results reported as approximately 0.44% to 0.93% of normal; for golodirsen: mean increase ~0.92% at week 48), but there are no satisfactory data establishing that these levels of truncated dystrophin translate into improved motor, pulmonary, or survival outcomes. Randomized and open‑label studies were limited by small sample sizes, post‑hoc comparisons to historical controls, and outcome variability (for example, the 6‑minute walk test), and confirmatory, adequately powered prospective trials are lacking, so the evidence is insufficient to conclude clinical effectiveness.

Because services determined to be not medically necessary are excluded from coverage, providers should not bill members for these services unless the member has been informed and has provided prior written agreement to continue treatment at their own expense. Providers should verify member benefits and coverage specifics using the appropriate Evidence of Coverage and the provider call center prior to delivering services.

Provider Responsibilities and Authorization

Prior Authorization

Prior Authorization and Benefit Verification

Prior authorization is not applicable for these therapies. However, benefit coverage and requirements may vary by member contract; providers should verify member-specific benefits prior to service.

Prior authorization: Not applicable
Verify member benefits with BCBSRI provider call center before rendering services

Denial Risk

Coverage Denial Triggers

Eteplirsen and golodirsen are not covered for the treatment of Duchenne muscular dystrophy. The following HCPCS codes associated with eteplirsen/golodirsen are flagged as not covered and claims will be denied when billed for this indication.

Eteplirsen/golodirsen are not covered for all indications including DMD
Affected HCPCS codes: see Coding section for specific not-covered codes

Note

Member Financial Liability for Non-Covered Services

When a service is determined to be non-covered under the member's benefit plan, providers may not bill or collect payment from the member unless the member has been informed in advance and has provided written agreement to accept financial responsibility. Refer to your participation agreement(s) for applicable provisions.

Non-covered services: do not bill member unless written advance agreement obtained
Verify subscriber/employer agreement and Evidence of Coverage for member liability rules

Documentation Required

Documentation and Benefit Verification

Benefits and coverage may vary between groups and contracts. Refer to the member's Evidence of Coverage and subscriber agreement for physician-administered drug benefits. Maintain documentation of benefit verification and any prior communications with the payer.

Verify eligibility and benefits per subscriber/employer agreement
Document benefit verification in the medical record and billing notes

Note

Standard Therapy Context

Corticosteroids are the current standard pharmacotherapy for Duchenne muscular dystrophy for all patients regardless of genetic variant. Manage corticosteroid therapy and supportive care per current clinical standards while adhering to coverage determinations for other therapies.

Standard therapy: corticosteroids for DMD regardless of genetic variant
Supportive management (cardiac, pulmonary, orthopedic, endocrine) should continue per clinical guidelines

Prior Authorization

Verify Member Benefits

Verify member-specific eligibility and benefits prior to providing services. Benefits and eligibility are governed by the member's Evidence of Coverage, subscriber certificate, and/or employer agreement; those documents supersede this policy. BCBSRI may review and revise this policy at any time.

Call the BCBSRI provider call center for member-specific benefit questions
Policy statements are informational and not a guarantee of payment

Clinical Background

Duchenne muscular dystrophy (DMD) is an X‑linked recessive progressive muscle‑wasting disorder caused by variants in the dystrophin gene that primarily affects males. Patients typically present in early childhood with motor difficulties and progressive weakness, commonly losing ambulation by around age 12 and later developing respiratory and cardiac complications. Eteplirsen and golodirsen are antisense oligonucleotide exon‑skipping therapies developed to induce skipping of exon 51 and exon 53, respectively, to produce an internally truncated dystrophin protein; both received accelerated FDA approval based on increased dystrophin expression but without confirmatory evidence of clinical benefit.

Key Definitions and Terms

Exon skipping agents — eteplirsen and golodirsen

Drug classAntisense oligonucleotides that induce exon skipping

Eteplirsen targetExon 51 skipping (Exondys 51; increases dystrophin production)

Golodirsen targetExon 53 skipping (Vyondys 53; increases dystrophin production)

MechanismRestore dystrophin reading frame to produce an internally truncated, partially functional dystrophin protein

Duchenne muscular dystrophy (DMD) definition

Inheritance patternX-linked recessive disorder

PathophysiologyVariants in the dystrophin gene disrupt the reading frame leading to absent/unstable dystrophin and progressive muscle degeneration

Clinical courseOnset in early childhood with progressive weakness, loss of ambulation by ~age 12, and later respiratory and cardiac complications

DiagnosisGenetic testing required to determine DMD gene variant(s) for definitive diagnosis

6-minute walk test (6MWT)

Test name6-minute walk test (6MWT)

Use in DMD studiesReferenced as a clinical endpoint in Duchenne muscular dystrophy natural history and treatment studies

Role for golodirsen confirmatory trialPrimary endpoint of the required randomized trial to verify clinical benefit (96 weeks, open-label extension to 144 weeks)

VYONDYS 53 prescribing label

ProductVYONDYS 53 (golodirsen) injection

Regulatory statusFDA accelerated (December 2019) approval for patients with DMD amenable to exon 53 skipping based on increased dystrophin

Labeling/outcomes citedPrescribing label documents dystrophin-related outcomes and is cited as the source for dystrophin and trial obligations

Postmarketing requirementFDA required a randomized double-blind, placebo-controlled trial with primary endpoint of 6MWT to verify clinical benefit

OpenPayer

Exondys (eteplirsen) and Vyondys (golodirsen) for Duchenne Muscular Dystrophy

Coverage Determination and Rationale

Billing Codes and Coverage Status

Provider Responsibilities and Authorization

Clinical Background

Key Definitions and Terms

J1428	Injection, eteplirsen, 10 mg
J1429	Injection, golodirsen, 10 mg